This report concerns a 4-month-old infant with progressive prominent and redness of his left eye since birth. This report concerns a 4-month-old infant with progressive prominent redness of his left eye since birth. Angiography revealed a congenital pial arteriovenous fistula between the temporal branch of the left posterior cerebral artery and left cavernous sinus through the sphenoparietal sinus, a condition not reported in the literature. The fistula was successfully occluded with two micro-coils by vertebrobasilar approach.
Arteriovenous Fistula/*diagnosis/therapy ; *Cavernous Sinus/radiography ; Embolization, Therapeutic/methods ; Humans ; Infant ; Intracranial Arteriovenous Malformations/*diagnosis/therapy ; Magnetic Resonance Imaging ; Male ; Posterior Cerebral Artery ; Temporal Lobe/blood supply

Objective:To explore the choice of skin flap design and clinical effects of skin soft tissue expansion in the treatment of body surface lesions.Methods:From January 2018 to December 2020, the Department of Plastic Surgery, the First Affiliated Hospital of the Air Force Medical University performed skin and soft tissue expansion in 148 patients with scars and nevus, including 83 males and 65 females. The age ranged from 4 to 52 years. According to the distance of the donor area, the expanded flap was divided into adjacent local flap and distal pedicled axial flap. An appropriate volume expander was embedded under the donor area flap. The expander was expanded regularly for 8-24 weeks, and the displacement of expander and other complications were avoided.Results:A total of 212 dilators were implanted in 148 patients, and the damaged area was completely repaired after 1 or 2 dilation operations. The expanded flaps were effectively used. The flap transfer was consistent with the first-stage design, with fewer auxiliary incisions, hidden and inconspicuous scars, and maximum repaired area was 22 cm×18 cm; the incidence of dilator complications (16 cases with 21 dilators) was 9.90%.Conclusions:Paying attention to the reasonable design and selection of flap in stage Ⅰ operation can make effective use of expanded flap in stage Ⅱ operation, fully repair body surface lesions, reduce auxiliary incision and achieve the best repair effect.

ObjectiveTo investigate the efficacy and safety of venlafaxine in the treatment of depression under the guidance of pharmacogenomics testing， and to provide references for individualized medication. MethodsA total of 66 patients who met the diagnostic criteria of International Classification of Diseases， tenth edition （ICD-10） for depressive episode were included in the study. Patients who were recommended to be treated with venlafaxine in the pharmacogenomics testing report were divided into study group （n=32）， and those who were decided to be treated with venlafaxine by doctors after consultation with patients were divided into control group （n=34）. At the baseline and the end of the 2^nd， 4^th， 6^th and 8^th weekend of treatment， Hamilton Depression Scale-24 item （HAMD-24） was adopted to evaluate the clinical efficacy. Meanwhile， Sheehan Disability Scale （SDS） was applied to measure the social function of patients at the baseline and the end of the 8^th weekend of treatment. After treatment， Treatment Emergent Symptom Scale （TESS） was used to assess the incidence of adverse reactions. ResultsAt the end of the 4^th， 6^th and 8^th weekend of treatment， HAMD-24 scores in the study group were all lower than those in the control group， with statistical differences （t=2.344， 4.316， 5.760， P<0.05 or 0.01）. At the end of the 8^th weekend of treatment， SDS score of the study group was lower than that of the control group， with statistical difference （t=2.173， P<0.05）. The adverse reaction rate in the study group was lower than that in the control group， with statistical difference （χ²=5.720， P<0.05）. ConclusionTreatment of depression with venlafaxine based on pharmacogenetic testing is an effective and safe way to alleviate the depression symptoms in patients.